VTGN Jan 2025 2.000 call
| Previous close | 1.6700 |
| Open | 1.6600 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 2.00 |
| Expiry date | 2025-01-17 |
| Day's range | 1.6600 - 1.6700 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Business WireVistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year
SOUTH SAN FRANCISCO, Calif., June 27, 2024--Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, announced today that for the second consecutive year it has been recognized by Mental Health America (MHA) for its dedication to promoting mental health and well-being in the workplace. Vistagen’s supportiv
Simply Wall St.Vistagen Therapeutics Full Year 2024 Earnings: EPS Beats Expectations
Vistagen Therapeutics ( NASDAQ:VTGN ) Full Year 2024 Results Key Financial Results Net loss: US$29.4m (loss narrowed by...
Insider MonkeyVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2024 Earnings Call Transcript
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2024 Earnings Call Transcript June 11, 2024 Operator: Greetings, and welcome to the Vistagen Therapeutics Fiscal Year-End 2024 Corporate Update Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. […]
